These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12874098)

  • 1. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension.
    Schiffrin EL; Amiri F; Benkirane K; Iglarz M; Diep QN
    Hypertension; 2003 Oct; 42(4):664-8. PubMed ID: 12874098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptors and cardiovascular remodeling.
    Schiffrin EL
    Am J Physiol Heart Circ Physiol; 2005 Mar; 288(3):H1037-43. PubMed ID: 15374828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat.
    Dana SL; Hoener PA; Bilakovics JM; Crombie DL; Ogilvie KM; Kauffman RF; Mukherjee R; Paterniti JR
    Metabolism; 2001 Aug; 50(8):963-71. PubMed ID: 11474486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR-alpha effects on the heart and other vascular tissues.
    Francis GA; Annicotte JS; Auwerx J
    Am J Physiol Heart Circ Physiol; 2003 Jul; 285(1):H1-9. PubMed ID: 12623780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity.
    Ferré P
    Diabetes; 2004 Feb; 53 Suppl 1():S43-50. PubMed ID: 14749265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues.
    Way JM; Harrington WW; Brown KK; Gottschalk WK; Sundseth SS; Mansfield TA; Ramachandran RK; Willson TM; Kliewer SA
    Endocrinology; 2001 Mar; 142(3):1269-77. PubMed ID: 11181544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall.
    Chinetti G; Fruchart JC; Staels B
    Z Kardiol; 2001; 90 Suppl 3():125-32. PubMed ID: 11374025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.
    Fruchart JC; Duriez P; Staels B
    Curr Opin Lipidol; 1999 Jun; 10(3):245-57. PubMed ID: 10431661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].
    Bocher V; Chinetti G; Fruchart JC; Staels B
    J Soc Biol; 2002; 196(1):47-52. PubMed ID: 12134632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells.
    Sugawara A; Takeuchi K; Uruno A; Ikeda Y; Arima S; Kudo M; Sato K; Taniyama Y; Ito S
    Endocrinology; 2001 Jul; 142(7):3125-34. PubMed ID: 11416035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.
    Neve BP; Fruchart JC; Staels B
    Biochem Pharmacol; 2000 Oct; 60(8):1245-50. PubMed ID: 11007963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy].
    Bełtowski J; Wójcicka G; Jamroz A
    Postepy Hig Med Dosw; 2003; 57(2):199-217. PubMed ID: 12866356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury.
    Yue TL; Bao W; Jucker BM; Gu JL; Romanic AM; Brown PJ; Cui J; Thudium DT; Boyce R; Burns-Kurtis CL; Mirabile RC; Aravindhan K; Ohlstein EH
    Circulation; 2003 Nov; 108(19):2393-9. PubMed ID: 14557369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
    Wayman NS; Hattori Y; McDonald MC; Mota-Filipe H; Cuzzocrea S; Pisano B; Chatterjee PK; Thiemermann C
    FASEB J; 2002 Jul; 16(9):1027-40. PubMed ID: 12087064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
    Iglarz M; Touyz RM; Viel EC; Paradis P; Amiri F; Diep QN; Schiffrin EL
    Hypertension; 2003 Oct; 42(4):737-43. PubMed ID: 12860836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and additional vascular effects of thiazolidinediones.
    Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
    Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptors and the cardiovascular system.
    Chen YE; Fu M; Zhang J; Zhu X; Lin Y; Akinbami MA; Song Q
    Vitam Horm; 2003; 66():157-88. PubMed ID: 12852255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.
    Cuzzocrea S; Pisano B; Dugo L; Ianaro A; Patel NS; Di Paola R; Genovese T; Chatterjee PK; Di Rosa M; Caputi AP; Thiemermann C
    Br J Pharmacol; 2003 Sep; 140(2):366-76. PubMed ID: 12970094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor ligands as antiatherogenic agents: panacea or another Pandora's box?
    Molavi B; Rasouli N; Mehta JL
    J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):1-8. PubMed ID: 12000972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.